In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

Published Date: 15 Dec 2023

FDA is now reviewing the experimental medication revumenib for KMT2A-rearranged disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Multiple Myeloma

2.

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

3.

GFR-TKIs taken orally in cancer patients who have artery dissection and aneurysms.

4.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

5.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot